{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-002187","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.622940+00:00","generated_at":"2026-05-16T11:25:04.348364+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CERo Therapeutics Phase 1 CER-1236 trial shows safety, 61-day transfusion-free interval; expands to MDS/MF","bullets":["First cohort completed DLT period with no CRS, ICANS, or treatment-related AEs reported.","Second patient (MDS/AML) had 61-day platelet transfusion-free interval after CER-1236 treatment.","FDA amendment filed to include advanced MDS and myelofibrosis as additional cohorts.","Company to host analyst call on Jan 7, 2026 at 5:00 PM ET to discuss progress and strategy."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-002187","json":"https://secwatch.observer/filing/0001213900-26-002187.json","markdown":"https://secwatch.observer/filing/0001213900-26-002187.md","text":"https://secwatch.observer/filing/0001213900-26-002187.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026002187/0001213900-26-002187-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026002187/ea0272086-8k_cero.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:25:04.348364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}